Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled (Older Adults, Aged >60 to 79 Years) and Open-Label (Adults, Aged 45 to 60 Years), Multicenter Trial to Investigate the Safety and Immunogenicity of a Dengue Tetravalent Vaccine (TDV) Administered Subcutaneously to Adults and Older Adults With or Without Comorbidities in Endemic Areas for Dengue
Conditions
Interventions
TDV
Placebo
Locations
7
Argentina
Fundacion Huesped - PPDS
Buenos Aires, Argentina
Associacao Obras Sociais Irma Dulce Hospital Santo Antonio
Salvador, Estado de Bahia, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS
São José do Rio Preto, São Paulo, Brazil
Singapore General Hospital (SGH)
Singapore, Singapore
Tan Tock Seng Hospital
Singapore, Singapore
Ramathibodi Hospital
Ratchathewi, Bangkok, Thailand
Start Date
January 20, 2026
Primary Completion Date
April 14, 2027
Completion Date
April 14, 2027
Last Updated
April 22, 2026
NCT07007585
NCT06665035
NCT06388785
NCT07432061
NCT06741683
NCT04514107
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions